# Transdermal and Topical Delivery Systems - Product Development and Quality Considerations - FDA Guidance Document

Source: https://www.keypedia.com/guidances/guidance-document/transdermal-and-topical-delivery-systems-product-development-and-quality-considerations/c271fdae-0acd-4bb8-a2b4-464dde75fe25

> FDA guidance document: Transdermal and Topical Delivery Systems - Product Development and Quality Considerations. Issue date: November 21, 2019. Get complete insights and analysis.

---

## Details

- Title: Transdermal and Topical Delivery Systems - Product Development and Quality Considerations
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2019-11-21
- Comment Close Date: 2020-02-19
- Last Changed: 2020-05-06
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2019-D-4447">FDA-2019-D-4447</a>

## Related Documents

- [Establishing Impurity Specifications for Antibiotics](https://www.keypedia.com/guidances/guidance-document/establishing-impurity-specifications-for-antibiotics/5bb8badb-7c32-4b76-bfc9-bbb8ab55fb84)
- [Quality Considerations for Topical Ophthalmic Drug Products](https://www.keypedia.com/guidances/guidance-document/quality-considerations-for-topical-ophthalmic-drug-products/19494a43-f26e-42c9-b1ad-99a1126b3d42)
- [Benefit-Risk Considerations for Product Quality Assessments](https://www.keypedia.com/guidances/guidance-document/benefit-risk-considerations-for-product-quality-assessments/dd4547d7-4ac9-437a-8d9b-b88b234da4bc)